Evopoint Biosciences and Everest Medicines Collaboration Advances with Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor XNW1011

December 4, 2024—Evopoint Biosciences announced that its partner Everest Medicines (HKEX 1952.HK) has reported positive results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001 capsules (also known as XNW1011), a novel Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of primary membranous nephropathy (pMN). XNW1011 is a next-generation, covalent, reversible BTK inhibitor developed in-house by Evopoint Biosciences. In September 2021, Suzhou Evopoint Biosciences Co., Ltd. (“Evopoint Biosciences” or “the Company”) licensed the global rights for the development, manufacturing, and commercialization of XNW1011 in the field of renal diseases to Everest Medicines.

Dr. Arthur Qiang , Chairperson of Evopoint Biosciences, commented, “XNW1011 is a covalent, reversible BTK inhibitor that has demonstrated outstanding performance in clinical studies. The promising results disclosed in Everest Medicines’ latest Preliminary Analysis of Phase 1b/2a Clinical Trial not only highlight the immense potential of XNW1011 but also signify a critical milestone in our licensing collaboration with Everest Medicines. ”

With robust R&D capabilities and an extensive innovative drug pipeline, Evopoint Biosciences continues to drive progress and innovation in the global pharmaceutical industry. This successful partnership with Everest Medicines is expected to further expand the Company’s global market presence and amplify its influence across the sector.